drugset / Trial / NCT00830076

A Study of the Effects of Co-Administration of Sitagliptin (MK-0431) and Metformin on Incretin Hormone Concentrations (MK-0431-110)

NCT00830076

Phase 1 Completed 18 enrolled Merck Sharp & Dohme LLC
RandomizedCrossoverDouble-blindTreatment

Summary

This study will assess the effects of sitagliptin and metformin alone and after co-administration on incretin hormone concentrations in patients with Type 2 diabetes.

Timeline

Start
2008-12-02
Primary completion
2009-04-30
Completion
2009-05-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 1000 mg
Subject Sitagliptin Small molecule 100 mg